



NEWS RELEASE

Contact: Arisaph Pharmaceuticals, Inc.
Christopher Kiritsy
President and CEO
(617) 292-3322

TRIAD PHARMACEUTICALS ADOPTS NEW NAME OF ARISAPH PHARMACEUTICALS

New name establishes unique identity and reflects company mission

BOSTON, MA November 14, 2005 – Triad Pharmaceuticals, Inc., a privately held drug discovery and design biopharmaceutical company, announced today that the Company is changing its name to Arisaph Pharmaceuticals, effective immediately. The Arisaph name establishes the Company’s unique identity. Moreover, Arisaph is derived from the ancient Greek language and reflects the Company’s goal of creating best-in-class or smart medicines to improve human health.

“The uniqueness of the Arisaph name symbolizes our differentiated approach to rational drug design, in which we leverage our strong medicinal chemistry expertise and our proprietary drug discovery technology platforms to create “ultra-smart” medicines,” said Christopher P. Kiritsy, President and Chief Executive Officer, of Arisaph Pharmaceuticals. “In our ongoing drug discovery programs, we have made significant progress in fulfilling our product development mission by designing three novel candidate drugs for cardiovascular disorders as well as two differentiated lead candidates for the treatment of type II diabetes.”

About Arisaph

Arisaph, located in Boston, Massachusetts, is an emerging drug discovery and design biopharmaceutical company with active development programs to develop differentiated therapies for diabetes, cancer and cardiovascular disease. Arisaph utilizes proprietary drug discovery platforms to develop “ultra-smart” drugs that are efficacious and act on select targets. Arisaph has successfully applied its specificity profiling and retro-inversal chiral chemistry technology platforms to synthesize promising candidate drugs for six different targets, including lead candidates for DPP IV inhibition to treat type II diabetes and for reverse D-4F, an orally active apo A-I mimetic peptide for treatment of atherosclerosis. Through a license agreement with Tufts University, the Company has exclusive worldwide rights to several important issued patents in the diabetes area and to all intellectual property generated by the Company.

Certain statements in this press release, including statements regarding the Company's research and development efforts, the Company's ability to successfully capitalize on the early stage research are forward-looking and are subject to risks and uncertainties. These risks and uncertainties include risks and uncertainties related to: our ability to discover and develop new compounds and products using a novel approach to drug discovery; the early stage of all of our discovery and development efforts; our ability successfully to complete preclinical and clinical development of our products; our ability to obtain and maintain regulatory approvals for our

products; competition from other technologies and technologies similar to ours; obtaining, maintaining and protecting intellectual property utilized by our products; changes in legislation and regulations affecting our products and potential product candidates; our need to obtain additional funding to support our business activities; our dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the effect of conditions in the pharmaceutical industry and the economy in general, as well as certain other risks and uncertainties.

###